# Zoetis Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Zoetis Inc.). ## Overview Zoetis Inc. is a U.S.-based animal health company focused on medicines, vaccines, diagnostics, biodevices, genetic tests, and precision animal health products. Its portfolio serves companion animals and livestock across more than 100 countries through direct sales and distributor channels. ## Products & services • Parasiticides for companion animals and livestock • Vaccines for disease prevention • Dermatology and pain management products • Anti-infectives and other pharmaceuticals • Animal health diagnostics and biodevices • Genetic tests and precision animal health services - **Parasiticides** (30%) — Products used to prevent and treat parasites in companion animals and livestock. - **Vaccines** (18%) — Immunization products for companion animal and livestock disease prevention. - **Dermatology** (14%) — Therapies for skin and allergy conditions in companion animals. - **Anti-infectives** (10%) — Antibiotic and infection-control products used mainly in livestock and veterinary care. - **Pain and Sedation** (8%) — Products used for pain control, anesthesia, and procedural sedation in animals. - **Diagnostics and Other Animal Health** (20%) — Diagnostics, biodevices, genetic tests, and other veterinary health services. - Parasiticides for companion animals and livestock - Vaccines for disease prevention - Dermatology and pain management products - Anti-infectives and other pharmaceuticals - Animal health diagnostics and biodevices - Genetic tests and precision animal health services ## Customers Zoetis sells primarily to veterinarians and livestock producers, with products often dispensed by prescription through veterinary practices. It also serves pet owners in markets where direct-to-consumer purchasing matters, and it uses distributors, retailers, and e-commerce in selected channels and geographies. - **Veterinarians** (primary) — Buy prescription medicines, vaccines, diagnostics, and support services for companion animals and livestock. - **Livestock producers** (primary) — Buy products for cattle, swine, poultry, fish, and sheep to manage herd health and productivity. - **Pet owners** (secondary) — Influence and sometimes purchase companion-animal products, especially where direct-to-consumer marketing matters. - **Distributors and buying groups** (secondary) — Purchase and resell products or negotiate on behalf of veterinary practices in non-direct markets. - Veterinarians buy prescription products and influence treatment protocols - Livestock producers buy herd-health products to protect productivity - Pet owners increasingly influence companion-animal purchasing decisions - Distributors support markets without a direct Zoetis commercial presence - Retail and e-commerce channels matter in selected companion-animal markets ## Geography Zoetis manages its business through two operating segments: the United States and International. It markets products in about 45 countries directly and sells in over 100 countries overall, with meaningful exposure to North America, Europe, Latin America, Asia, Australia, and Africa. - **United States** (50%) - **International** (50%) - Two operating segments: United States and International - Direct commercial presence in about 45 countries - Products sold in over 100 countries worldwide - Emerging markets include Brazil, Chile, China, and Mexico - International results are exposed to foreign exchange movements ## Strategy Zoetis focuses on broadening its animal health portfolio across companion animals and livestock while maintaining direct relationships with veterinarians and producers. Its strategy also relies on R&D, product innovation, and selective acquisitions to expand diagnostics, genetics, and specialty animal health capabilities. - **Product innovation and lifecycle expansion** (medium-term) — New and improved products help address unmet animal-health needs and sustain relevance across species. - **Direct customer engagement** (short-term) — Sales representatives and veterinary specialists help influence prescribing and build loyalty. - **Geographic expansion and local market coverage** (medium-term) — Local presence improves access to veterinarians and producers and supports emerging-market growth. - **Selective acquisitions and capability building** (medium-term) — Acquisitions can add products, diagnostics, manufacturing capacity, and research capabilities. - Expand innovation across medicines, vaccines, diagnostics, and genetics - Use direct sales and technical support to deepen customer relationships - Broaden companion-animal and livestock portfolios across species - Use acquisitions to add diagnostics, R&D capabilities, and capacity - Maintain global reach through direct channels and distributors ## Risks Zoetis faces customer concentration and channel-consolidation pressure, especially as veterinarians, livestock producers, and distributors gain buying power. It is also exposed to trade policy changes, tariffs, supply-chain disruption, foreign exchange volatility, cyber risk, and regulatory or market shifts affecting animal-health products and antibacterials. - **Customer and distributor consolidation** [high] — Larger veterinary groups, buying cooperatives, and distributors can demand lower prices. - **Tariffs and trade restrictions** [high] — Higher duties can increase raw material, component, and finished-goods costs and disrupt supply chains. - **Foreign exchange volatility** [medium] — International revenue and earnings are translated from multiple currencies into U.S. dollars. - **Cybersecurity and IT disruption** [high] — Operational dependence on systems and remote work increases exposure to attacks and outages. - **Generic competition and channel change** [medium] — Generic products or shifts toward retail/e-commerce can reduce share and pricing power. - Customer and distributor consolidation can pressure pricing - Tariffs and trade restrictions can raise input and logistics costs - Foreign exchange can reduce reported International revenue - Cyberattacks could disrupt operations and damage customer trust - Generic competition and channel shifts can erode share - Regulatory changes can affect antibacterials and product approvals ## Accounting Zoetis’ reported revenue is affected by estimated deductions for returns and revenue incentives, so timing and assumptions can move quarterly results. Investors should also watch goodwill and intangible asset impairment, fair value judgments in acquisitions, and contingencies, because the company relies on acquisitions and has a large portfolio of acquired and developed intangibles. - **Revenue deductions and incentives** — Can affect revenue timing and margin comparability across periods - **Goodwill and intangible asset impairment** — Could create non-cash charges if product or business values decline - **Fair value in acquisitions** — Affects purchase accounting, amortization, and future earnings - **Contingencies and tax estimates** — May create volatility in provisions and effective tax rate - Revenue deductions are estimated for returns and incentives - Quarterly results can be affected by distributor stocking and seasonality - Goodwill and indefinite-lived intangibles require annual impairment testing - Acquisition accounting affects fair value of assets and liabilities - Contingencies and tax estimates can change reported earnings --- *Last updated: 2026-08-11T04:03:56.228997+00:00*